COVID-19 Pneumothorax in the United Kingdom: a prospective observational study using the ISARIC WHO clinical characterisation protocol. by Marciniak, Stefan J et al.
Early View 
Research letter 
COVID-19 Pneumothorax in the United Kingdom: 
a prospective observational study using the 
ISARIC WHO clinical characterisation protocol 
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is 
published here in its accepted form prior to copyediting and typesetting by our production team. After 
these production processes are complete and the authors have approved the resulting proofs, the article 
will move to the latest issue of the ERJ online. 
Copyright ©The authors 2021. This version is distributed under the terms of the Creative Commons 
Attribution Licence 4.0.
Stefan J. Marciniak, James Farrell, Anthony Rostron, Ian Smith, Peter J. M. Openshaw, J. Kenneth 
Baillie, Annemarie Docherty, Malcolm G. Semple 
Please cite this article as: Marciniak SJ, Farrell J, Rostron A, et al. COVID-19 Pneumothorax in 
the United Kingdom: a prospective observational study using the ISARIC WHO clinical 
characterisation protocol. Eur Respir J 2021; in press (https://doi.org/10.1183/13993003.00929-
2021). 
COVID-19 Pneumothorax in the United Kingdom: a prospective 
observational study using the ISARIC WHO clinical characterisation 
protocol 
 
Stefan J Marciniak#*1,2, James Farrell*3, Anthony Rostron4,5, Ian Smith6, Peter JM Openshaw7, J 




Corresponding author: Professor Stefan J. Marciniak FRCP PhD 
Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge CB2 0XY, 
UK; Telephone: +44 1223 762660; Email: sjm20@cam.ac.uk 
Email: sjm20@cam.ac.uk; Twitter: @Prof_Marciniak; Tel: +44 1223 762660 
 
Funding sources:  This work is supported by grants from: the National Institute for Health 
Research (NIHR; award CO-CIN-01), the Medical Research Council (MRC; grant MC_PC_19059), 
and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at 
University of Liverpool in partnership with Public Health England (PHE), in collaboration with 
Liverpool School of Tropical Medicine and the University of Oxford (award 200907), NIHR HPRU 
in Respiratory Infections at Imperial College London with PHE (award 200927), Wellcome Trust 
and Department for International Development (DID; 215091/Z/18/Z), the Bill and Melinda Gates 
Foundation (OPP1209135), Liverpool Experimental Cancer Medicine Centre (grant reference 
C18616/A25153), NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) NIHR 
Imperial College London Biomedical Research Centre (IS-BRC-1215-20013), EU Platform for 
European Preparedness Against (Re-)emerging Epidemics (PREPARE; FP7 project 602525), and 
NIHR Clinical Research Network for providing infrastructure support for this research. 
 
Take home message: Population level data from 131,679 patients show that COVID-19 
pneumothorax occurs in 0.97% of admitted patients, especially males and smokers, and is 
associated with increased mortality. 
 
 
1 CIMR, University of Cambridge, Cambridge, CB2 0XY, UK 
2 Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0QQ 
3 Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, 
Edinburgh, EH16 4UX 
4 Integrated Critical Care Unit, Sunderland Royal Hospital, South Tyneside and Sunderland NHS 
Foundation Trust 
5 Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne 
NE1 7RU 
6 South Tyneside and Sunderland NHS Foundation Trust, Sunderland, SR4 7TP 
7 Royal Papworth Hospital, Cambridge, CB2 0AY 
8 Imperial College London, Respiratory Medicine, London, SW7 2AZ 
9 Roslin Institute, University of Edinburgh, Midlothian, EH25 9RG 
10 MRC Human Genetics Unit, University of Edinburgh, Crewe Road, Edinburgh EH4 2X 
11 Intensive Care Unit, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA 
12 NIHR Health Protection Research Unit in Emerging and Zoonotic Infection Institute of Infection 
and Global Health, University of Liverpool, Liverpool, L69 7BE 
 
  
To the Editor: 
Pneumothorax is an important complication of COVID-19 (1, 2). Based on a series of 60 
individuals, we previously estimated that 0.91% of people admitted to hospital with COVID-19 
develop pneumothorax (1). Males accounted for three quarters of those affected, and patients 
requiring non-invasive or invasive ventilatory support appeared at elevated risk. In a separate 
series of ventilated patients with COVID-19, barotrauma, defined as pneumothorax or 
pneumomediastinum, was found to be an independent risk for death (2). During the pandemic, 
treatment strategies have evolved, influenced by large randomised controlled trials and clinical 
experience. Following the landmark results from the RECOVERY trial (3), dexamethasone 
became standard of care for patients requiring supplemental oxygen. Following the first UK wave 
between March to June 2020, use of non-invasive respiratory support became more common (4, 
5). Such changes could plausibly alter the incidence of pneumothorax caused by COVID-19. 
Indeed, a recent small study reported an increase in pneumothoraces in the second wave of 
COVID-19 in Italy, speculating that dexamethasone use might have been causal (6).  
 
To examine COVID-19 pneumothorax at a population level during the first and second waves in 
the UK, we analysed data from the International Severe Acute Respiratory and emerging 
Infections Consortium (ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK). The study 
is being performed by the ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC4C) 
in 311 hospitals across England, Scotland, and Wales (National Institute for Health Research 
Clinical Research Network Central Portfolio Management System ID 14152)(7). Approval was 
granted by the following Ethics Committees: South Central-Oxford (Ref 13/SC/0149), Scotland 
(Ref 20/SS/0028), and WHO (RPC571, RPC572). Routine health data collation did not require 
consent.  
 
From its activation on 17th January 2020 to 15th February 2021, 131,679 patients aged ≥18 years 
were recruited to CCP-UK if they were admitted to hospital with a positive SARS-CoV-2 PCR or 
were considered highly clinically likely to have COVID-19. Of these, 1,283 (0.97%) had a 
pneumothorax at some stage during their admission; 68.5% (879/1,283) of those with a 
pneumothorax were male (Fig 1A). Taking 15th August as the boundary between the first and 
second waves of the pandemic, 56.1% (720) of pneumothoraces occurred during the first wave 
with an overall incidence of 1.01% (720/70,969). During the first 6 months of the second wave, the 
incidence of pneumothorax was not significantly different at 0.93% (563/60,710, p=0.12).  
 
The incidence of pneumothorax differed between groups defined by the level of respiratory 
support they received. In patients requiring no supplemental oxygen, only 0.16% (60/37,030) had 
a pneumothorax; of those requiring oxygen without pressure support 0.56% (396/70,609) had 
pneumothoraces; treatment with non-invasive respiratory support alone was associated with an 
incidence of 0.96% (137/14,251); while significantly more patients (6.1%, 195/3,182) who received 
invasive ventilation also had a pneumothorax (p=0.004)(Fig 1B). Patients who received both non-
invasive respiratory support and invasive ventilation had the highest incidence of pneumothorax at 
8.5% (491/5,749, p<0.0001). It is noteworthy that despite an overall similar incidence of 
pneumothoraces during the first and second waves, the incidence of pneumothorax in patients 
who received both non-invasive respiratory support and invasive ventilation during their admission 
was lower in the first than the second wave (6.9% vs 11.2%, p<0.001)(Fig 1B). Among patients 
who did not receive corticosteroid treatment, 0.70% (598/85,961) developed a pneumothorax 
versus 1.46% (609/41,798) in those who did (p<0.001). Without steroids, pneumothoraces 
occurred in 4.94% (89/1,800) of patients who received invasive ventilation vs 6.31% (149/2,363) of 
patients who received both non-invasive respiratory support and invasive ventilation. Of patients 
treated with steroids, 7.57% (86/1,136) treated with invasive ventilation vs 10.36% (309/2,983) 
who received non-invasive respiratory support and invasive ventilation suffered pneumothoraces 
(Fig 1C). However, after adjusting for respiratory severity on admission (respiratory rate and 
peripheral oxygen saturation) and co-morbidities, corticosteroid therapy was not independently 
associated with increased incidence of pneumothorax either in critical care (intensive care unit, 
ICU, or high dependency unit, HDU) or non-critical care populations (p = 0.20 and 0.65 
respectively). 
 
In patients on non-critical care wards, asthma was not associated with pneumothorax after 
adjustment for age, sex and respiratory severity on admission, although “chronic pulmonary 
disease” (which includes chronic obstruction pulmonary disease, interstitial lung disease, and 
sarcoidosis) was associated with pneumothorax with an odds ratio (OR) of 1.80 (1.37-2.36, 
p<0.001)(Fig 1D). Former and current smokers were at increased risk: OR 1.44 (1.10-1.90, 
p=0.009) and 2.28 (1.60-3.22, p<0.001) respectively (Fig 1D). These associations did not translate 
to the critical care population where respiratory co-morbidities and smoking were not significant 
predictors of pneumothorax (Fig 1D). Restricting the analysis to patients not on pressure support, 
respiratory severity was not associated with increased risk of pneumothorax in both non-critical 
care and critical care populations.  
 
In this series, pneumothorax with COVID-19 was associated with a worse prognosis. Adjusted for 
age, sex, and comorbidities, the OR for death was 2.94 (2.26-3.81; p<0.001) in non-critical care 
patients with pneumothorax compared to those without (Fig 1E). For critical care patients, the 
adjusted OR for death was 2.98 (2.47-3.60; p<0.001)(Fig 1F). Further analysis in both non-critical 
care and critical care populations showed that the OR of interaction terms between pneumothorax, 
age, sex and co-morbidities were not significant in predicting death. This suggests that the 
increased risk of death from pneumothorax was similar across subgroups. 
 
There are several limitations to this study. The data collected from three London sites are 
excluded after 15th November 2020 due to unreliable classification of ICU patients. Inevitably, 
there are missing data, but the relatively low numbers are unlikely to impact the results. The case 
report form (CRF) of ISARIC does not request information on the timing of pneumothoraces and 
so we are unable to establish whether pneumothoraces occurred following the introduction of 
ventilatory support or if the presence of a pneumothorax resulted in respiratory deterioration 
requiring intubation. The CRF does not include history of previous pneumothorax nor treatment of 
pneumothorax. The CRF does not include pneumomediastinum, so we are unable to comment on 
this related complication. The lack of randomisation in any observational study makes attribution of 
causality impossible. Therefore, we are unable to determine whether the increased incidence of 
pneumothorax in ventilated patients reflects severity of disease or is iatrogenic. In this regard, the 
RECOVERY-RS (Respiratory Support) trial may shed light on the relationship between ventilatory 
support and pneumothorax (8). The place of non-invasive respiratory support requires further 
study, since those who failed to respond to this and then required invasive ventilation appeared at 
greater risk of pneumothorax than those who underwent early intubation and mechanical 
ventilation. 
 
Pneumothorax and pneumomediastinum have emerged as important complications of COVID-19 
(1, 2, 9). Our previous smaller series suggested an incidence of 0.91% (1), similar to the 1.7% 
reported for SARS caused by SARS-CoV-1 (10). We now confirm using ISARIC data, which 
covers 40-45% of patients hospitalised for COVID-19 in England, Wales and Scotland, that 0.97% 
suffer a pneumothorax, but there are marked differences between subgroups. These may reflect 
disease severity, but we are unable to exclude an iatrogenic component. We report a clear 
association between incident pneumothorax and invasive mechanical ventilation. Pneumothorax 
had also been reported in patients with Middle East Respiratory Syndrome (MERS)-related 
coronavirus infection, and as with SARS, pneumothorax was a marker of poor prognosis (10, 11). 
Although in our previous small study we observed increased mortality only in patients >70 years of 
age, our current large series reveals that pneumothorax is independently associated with mortality 
over a wider age range.  
 
In summary, we report data from the ISARIC4C study of 131,679 patients admitted with COVID-19 
that reveal an overall incidence of pneumothorax of 0.97%. Male sex, smoking, chronic pulmonary 
disease and invasive ventilation were associated with increased risk of pneumothorax. 
Pneumothorax is associated with increased mortality in COVID-19.  
  
 
Legend: COVID-19 pneumothorax in the ISARIC4C dataset. 
(A) Histogram of incidence of pneumothoraces over time (absolute numbers, light grey females, 
dark grey males); line graph of pneumothorax incidence (percentage ± 95% confidence interval). 
(B) Incidence of pneumothorax by age, ventilatory support and pandemic wave. (C) Incidence of 
pneumothorax by age, ventilatory support and steroid therapy: NIV = non-invasive respiratory 
support. IMV = invasive respiratory support. (D) Demographics and risk factors for pneumothorax 
in non-critical care and critical care patients. Critical care patients include those admitted to an 
intensive care unit (ICU) or high dependency unit (HDU). Sample size for multivariable analysis 
was n = 61,046 and 10,719 for non-critical care and critical care populations respectively. (E) Risk 
factors for death in patients in non-critical care patients. (F) Risk factors for death in critical care 
patients. 
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